Dr Nadia Harbeck (Munich, Germany) presented results from the phase 3 DESTINY-Breast 11 trial (NCT05113251), comparing neoadjuvant trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) versus dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in adults with untreated high-risk HER2-positive early breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.